Theriva Biologics Statistics
Want to see TOVX full AI Analyst Report?
Theriva Biologics (TOVX) Stock Statistics & Valuation Metrics
Total Valuation
Theriva Biologics has a market cap or net worth of $6.61M. The enterprise value is $5.28M.
- Market Cap
- $6.61M
- Enterprise Value
- $5.28M
Share Statistics
Theriva Biologics has 45,892,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,892,670
- Owned by Insiders
- 0.57%
- Owned by Institutions
- 2.80%
Financial Efficiency
Theriva Biologics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -52.10%.
- Return on Equity (ROE)
- -1.64
- Return on Assets (ROA)
- -0.66
- Return on Invested Capital (ROIC)
- -52.10%
- Return on Capital Employed (ROCE)
- -0.53
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.58M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Theriva Biologics is -0.58. Theriva Biologics’s PEG ratio is -0.00.
- PE Ratio
- -0.58
- PS Ratio
- 22.04
- PB Ratio
- 0.62
- Price to FCF
- -0.61
- Price to Operating Cash Flow
- -0.61
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Theriva Biologics had revenue of 0 and earned -25.25M in profits. Earnings per share was -2.08.
- Revenue
- 0
- Gross Profit
- -108.00K
- Operating Income
- -15.02M
- Pretax Income
- -23.74M
- Net Income
- -25.25M
- EBITDA
- -23.63M
- Earnings Per Share (EPS)
- -2.08
Cash Flow
In the last 12 months, operating cash flow was -10.89M and capital expenditures -11,000, giving a free cash flow of -10.90M billion.
- Operating Cash Flow
- -10.89M
- Free Cash Flow
- -10.90M
- Free Cash Flow per Share
- -0.24
Dividends & Yields
Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -164.90%
- Earnings Yield
- -131.98%
Stock Price Statistics
- Beta
- 1.36
- 52-Week Price Change
- -47.64%
- 50-Day Moving Average
- 0.21
- 200-Day Moving Average
- 0.24
- Relative Strength Index (RSI)
- 28.06
- Average Volume (3m)
- 1.88M
Important Dates
Theriva Biologics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Theriva Biologics as a current ratio of 1.74, with Debt / Equity ratio of 17.09%
- Current Ratio
- 1.74
- Quick Ratio
- 1.74
- Debt to Market Cap
- 0.89
- Net Debt to EBITDA
- 0.44
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Theriva Biologics has paid 1.51M in taxes.
- Income Tax
- 1.51M
- Effective Tax Rate
- -0.06
Enterprise Valuation
Theriva Biologics EV to EBITDA ratio is -0.18, with an EV/FCF ratio of -0.14.
- EV to Sales
- 5.22
- EV to EBITDA
- -0.18
- EV to Free Cash Flow
- -0.14
- EV to Operating Cash Flow
- -0.14
Balance Sheet
Theriva Biologics has $8.47M in cash and marketable securities with $3.43M in debt, giving a net cash position of $5.05M billion.
- Cash & Marketable Securities
- $8.47M
- Total Debt
- $3.43M
- Net Cash
- $5.05M
- Net Cash Per Share
- $0.11
- Tangible Book Value Per Share
- -$0.18
Margins
Gross margin is -419.67%, with operating margin of -2997.67%, and net profit margin of -2909.33%.
- Gross Margin
- -419.67%
- Operating Margin
- -2997.67%
- Pretax Margin
- -2909.33%
- Net Profit Margin
- -2909.33%
- EBITDA Margin
- -2877.00%
- EBIT Margin
- -2909.33%
Analyst Forecast
The average price target for Theriva Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 95.48%
Scores
- Smart Score
- ―
- AI Score
- 42

